Health Canada is investigating the use of non-steroidal anti-inflammatory drugs (NSAIDs) at 20 weeks or later in pregnancy and the rare, but serious, risk of kidney problems in an unborn baby, in response to a Drug Safety Communication recently released by the U.S. Food and Drug Administration (FDA) on this issue.
OTTAWA – Benzodiazepines and benzodiazepine-like prescription drugs (commonly referred to as “Z-drugs)—commonly used to treat sleep and anxiety disorders, certain seizure disorders, and to help relax muscles or relieve muscle pain—can lead to problematic use and substance use disorder. To help mitigate these risks, Health Canada is asking manufacturers to update their safety warnings to include more prominent and consistent messaging for patients and healthcare professionals.
Product: ATLAS - Codeine phosphate syrup 5 mg/mL (DIN 00050024) lot number 35MC, expiry date 2023-03, Laboratoire Atlas Inc. Issue: One lot of ATLAS - Codeine phosphate syrup 5 mg/mL is being recalled because some bottles contain isopropyl rubbing alcohol 70%. What to do: Stop taking product from the affected lot and obtain a replacement product from your pharmacist. Consult with your doctor or pharmacist if you have any questions or concerns.